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Monitoring of minimal residual disease (MRD) has
become routine clinical practice in frontline treatment of
virtually all childhood acute lymphoblastic leukemia (ALL)
and many adult ALL patients [1]. MRD diagnostics has
proven to be the strongest prognostic factor, allowing for
risk group assignment into different treatment arms,
resulting in significant treatment reduction or mild or
strong intensification. Within the Dutch Childhood
Oncology Group (DCOG) ALL10 protocol, MRD-based low-
risk patients received significant treatment reduction,
resulting in an excellent outcome with very few side
effects [2].
Given the significant treatment reduction of MRD-
negative patients within the DCOG-ALL10 protocol, the
strict criteria of the MRD-based low-risk group of the ori-
ginal I-BFM-SG study [3] have been retained to define
MRD negativity, using at least two different types of sen-
sitive immunoglobulin (IG)-T-cell receptor (TR) polymerase
chain reaction (PCR) targets, thereby avoiding or reducing
oligoclonality problems and related false negativity [3–5].
Table 1. Results of STR analysis and possible explanation by cytogenetic findings.
Patient STR analysis Cytogenetics
Difference in STR
explained?
LR-02 vWA (12p) shift in Dx 55, XY, þX, dup(1)(q2?1q4?2), þ4, þ6, þ10, þ14, þ17, þ18,
þ21, þ21[16]/46,XY[3]
No
LR-05 D16S539 (16q) missing in Dx 47, XX, þX, add(2)(p1?1), add(3)(q2?5), 13, 16, 17, 17,
19, 20, þ21c, þ5mar[7]/48, idem, þ8[9]/47, XX, þ21c[4]
Yes
LR-11 D7S820 (7q) extra peak in Dx 46, XY, t(6;7)(q23;q34)[6]/46, XY[5] yes
IR-05 D13S317 (13q) missing in Dx; vWA (12p)
missing in Dx
45, XY, add(7)(q3?6), add(12)(p1?3), 13[12]/46, XY[6]
FISH: t(12;21) present
Yes
LR-16 CSF1PO (5q) missing in Dx; vWA (12p)
missing in Dx
46, XY, del(2)(q22q31), add(12)(p1?2), del(12)(p11)[7]/




LR-30 vWA (12p) missing in Dx 46, XX, del(2)(q3?2q34)[11]/46, XX[2] No
IR-16 THO (11p) missing in Dx 56 59, XX, þX[12], þX[3], der(2;22)(q10;q10), þ4, þ4[8],
þ6, þ8[7], þ10, þ14[11], þ16[3], þ17[5],
þadd(17)(q25)[9], þ18, þ21, 22, þ1 4mar[cp13]/46, XX[6]
No
IR-21 D7S820 (7q), CSF1PO (5q), THO1 (11p),
D2S1338 (2q), D19S433 (19q), vWA
(12p), TPOX (2p), D5S818 (5q), FGA
(4q) all missing in Dx
28< n>,X,þY,þ10,þ14,þ18,þ21[11]/46,XY[3] Yes
IR-26 D16S539 (16q) missing in Dx 45,X,-Y,del(6)(q1?6q22),del(9)(p21p2?3),del(12)(p13),del(12)(q2?3),
der(16)del(16)(p11p12)add(16)(q11)[11]/46,XY[2]
Yes
IR-30 vWA (12p) missing in Dx 45, XX, del(1)(p11), der(9)t(9;14)(p1?3;q1?1), der(13;22)(q10;q10),
14, þ21c[5]/
45, idem, þ1, del(1)(p11), add(12)(p1?), 20, þmar1[5]/
44, idem, þadd(1)(p1?2), del(1)(p11), add(7)(p2?1), 12[11]/
47, XX, þ21c[3]
FISH: t(12;21) present with loss of normal 12p13/ETV6
Yes
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However, false negativity may also be caused by mixing
up patient samples [6,7], resulting in under-treatment of
the corresponding patient and increased relapse risk. We
used short tandem repeat (STR) analysis to evaluate
whether sample mix-up occurred in low-risk (LR) ALL
patients treated within the DCOG-ALL10 protocol.
The DNA samples from 30 LR patients used for MRD
diagnostics at diagnosis, day 33 and day 78 were eval-
uated by STR analysis using the PowerPlexVR 16 system
(Promega, Leiden, the Netherlands). This kit evaluates 15
tetranucleotide repeat loci on different chromosomal
positions. In addition, diagnostic and day 33 samples
from 20 intermediate risk (IR; MRD positive at day 33,
therefore confirmed not to be mixed up) were used for
comparison.
In five out of 30 LR patients (16.7%), differences were
observed between the diagnostic sample and the follow-
up sample(s) in one or more evaluated STR (Table 1 and
Figure 1(A)). Of note, for the LR patients, the STR patterns
in the two follow-up samples were always identical, sug-
gesting that sample mix up was unlikely. This was sup-
ported by the finding that also in 5 out of 20 (25%) IR
Figure 1. STR results of patient IR-16. (A) Diagnostic sample (top row) versus follow-up (bottom row). In the diagnostic sample,
an STR for THO (11p) seems missing as compared to the follow-up sample. (B) Nonsorted cells (top row) versus sorted ALL cells
(middle row) and sorted normal cells (bottom row) of the same patient clearly show specific loss of a STR in the leukemic cells.
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patients differences in one or more STRs were observed
(Table 1). Therefore, instead of a results of sample mix
up, the differences in STR pattern more likely are related
to differences between leukemic cells (predominant in
the diagnostic sample) and normal cells (predominant in
the follow-up samples). We therefore evaluated these 10
cases with STR differences with respect to their cytogen-
etic findings. Indeed, in seven out of 10 cases, the differ-
ence in STR pattern could be explained by the
chromosomal abnormalities in the leukemic cells
(Table 1). Three cases (LR-02; LR-30 and IR-16), however,
could not be explained by the cytogenetic data. For
these cases, both the leukemic cells and normal cells
from the (viably frozen) diagnostic sample were separated
by FACS-sorting and STR was performed on the sorted
cell populations. In all three cases, the STR pattern in the
sorted normal cells from diagnosis was similar to the STR
pattern in the follow-up samples, whereas the STR pat-
tern of the sorted leukemic cells was different (and identi-
cal to the STR pattern of the nonsorted diagnostic
sample) (Figure 1(B)). These data therefore further con-
firm that the different STR pattern between diagnosis and
follow-up is not related to sample mix up but indeed
reflects the genetic abnormalities present in the leukemic
cells. MLPA analysis (SALSA MLPA P335 ALL-IKZF1 probe
mix; MRC-Holland, Amsterdam, the Netherlands) was per-
formed in these three patients. In patient LR-30, a dele-
tion of the ETV6 gene on 12p13 was observed by FISH,
whereas by STR analysis one allele for VWF on 12p12 was
lost, suggesting a deletion both comprising 12p12 and
12p13. In the two other patients, MLPA analysis did not
explain the STR data. It may be expected that also in
patient IR-16 the missing THO STR is due to a small
chromosomal deletion not detected by routine cytogen-
etics. We have no explanation for the shift in the VWF
STR in patient LR-02, but genetic changes in the leukemic
cells apparently occurred in this locus.
Our data show that sample mix up had not occurred
in the LR patients evaluated in this study. In addition, our
data show that the interpretation of STR data from sam-
ples obtained from leukemic patients, comparably to
patients with other malignancies [8–10], is not always
straight-forward but can be hampered by changes in the
STR pattern caused by genetic changes in the malignant
cells. Results of subsequent STR analyses should therefore
be interpreted with care.
Potential conflict of interest: Disclosure forms provided
by the authors are available with the full text of this
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